Skip to content

Study · Animal study (in vivo) · mouse · 2017

9 results

The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age.

Sweetwyne MT, Pippin JW, Eng DG, Hudkins KL, Chiao YA, Campbell MD, Campbell MD, Marcinek DJ, Alpers CE, Szeto HH, Rabinovitch PS, Shankland SJ

Kidney international4 Jan 2017Cited by 98 (Europe PMC)

PMID28063595 (opens in a new tab)PMCIDPMC5392164 (opens in a new tab)DOI10.1016/j.kint.2016.10.036 (opens in a new tab)PepBankPUB-28063595
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In aged mice, SS‑31 treatment improved age-related mitochondrial morphology in glomeruli versus saline.

    In plain wordsIn old mice, SS‑31 treatment improved the shape of the energy-producing parts (mitochondria) in kidney filters compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Direction not reportedAge-related mitochondrial morphology
    Study

    mousen: not reported in source

    aged mice (26 months), glomerular architecture
    Comparator
    Saline
    Outcome group
    Mitochondrial function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    SS-31 treatment improved age-related mitochondrial morphology and glomerulosclerosis.
    1 context sentence
    Summary · context
    Baseline (24-month-old) mice were randomized to receive 8 weeks of SS-31, or saline, and killed at 26 months of age.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In aged mice, SS‑31 treatment improved age-related glomerulosclerosis versus saline.

    In plain wordsIn old mice, SS‑31 treatment improved scarring of the kidney filters compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseAge-related glomerulosclerosis
    Study

    mousen: not reported in source

    aged mice (26 months), glomerular architecture
    Comparator
    Saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    SS-31 treatment improved age-related mitochondrial morphology and glomerulosclerosis.
    1 context sentence
    Summary · context
    Baseline (24-month-old) mice were randomized to receive 8 weeks of SS-31, or saline, and killed at 26 months of age.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In aged mice, SS‑31 reduced glomerular senescence markers (p16 and senescence-associated-ß-Gal) versus saline.

    In plain wordsIn old mice, SS‑31 lowered markers of cell aging in the kidney filters compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseGlomerular senescence markers (p16, senescence-associated-ß-Gal)
    Study

    mousen: not reported in source

    aged mice (26 months), glomerular architecture
    Comparator
    Saline
    Outcome group
    Aging markers · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    SS-31 reduced senescence (p16, senescence-associated-ß-Gal)
    1 context sentence
    Summary · context
    Baseline (24-month-old) mice were randomized to receive 8 weeks of SS-31, or saline, and killed at 26 months of age.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In aged mice, SS‑31 increased the density of parietal epithelial cells in glomeruli versus saline.

    In plain wordsIn old mice, SS‑31 increased the density of parietal epithelial cells in the kidney filters compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseParietal epithelial cell density
    Study

    mousen: not reported in source

    aged mice (26 months), glomerular architecture
    Comparator
    Saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    increased the density of parietal epithelial cells.
    1 context sentence
    Summary · context
    Baseline (24-month-old) mice were randomized to receive 8 weeks of SS-31, or saline, and killed at 26 months of age.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In aged mice, SS‑31 reduced markers of parietal epithelial cell activation (Collagen IV, pERK1/2 and α-smooth muscle actin) versus saline.

    In plain wordsIn old mice, SS‑31 lowered markers of activation of parietal epithelial cells in the kidney filters compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseParietal epithelial cell activation markers (Collagen IV, pERK1/2, α-smooth muscle actin)
    Study

    mousen: not reported in source

    aged mice (26 months), glomerular architecture
    Comparator
    Saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    However, SS-31 treatment reduced markers of parietal epithelial cell activation (Collagen IV, pERK1/2, and α-smooth muscle actin).
    1 context sentence
    Summary · context
    Baseline (24-month-old) mice were randomized to receive 8 weeks of SS-31, or saline, and killed at 26 months of age.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In aged mice, SS‑31 did not change podocyte density versus saline.

    In plain wordsIn old mice, SS‑31 did not change the number of podocytes (kidney filter cells) compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changePodocyte density
    Study

    mousen: not reported in source

    aged mice (26 months), glomerular architecture
    Comparator
    Saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    SS-31 did not impact podocyte density
    1 context sentence
    Summary · context
    Baseline (24-month-old) mice were randomized to receive 8 weeks of SS-31, or saline, and killed at 26 months of age.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In aged mice, SS‑31 reduced the podocyte injury marker desmin versus saline.

    In plain wordsIn old mice, SS‑31 lowered a marker of injury to podocytes (kidney filter cells) compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePodocyte injury marker (desmin)
    Study

    mousen: not reported in source

    aged mice (26 months), glomerular architecture
    Comparator
    Saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    it reduced markers of podocyte injury (desmin) and improved cytoskeletal integrity (synaptopodin).
    1 context sentence
    Summary · context
    Baseline (24-month-old) mice were randomized to receive 8 weeks of SS-31, or saline, and killed at 26 months of age.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In aged mice, SS‑31 improved podocyte cytoskeletal integrity, measured by synaptopodin, versus saline.

    In plain wordsIn old mice, SS‑31 improved the internal structure of podocytes (kidney filter cells) compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreasePodocyte cytoskeletal integrity (synaptopodin)
    Study

    mousen: not reported in source

    aged mice (26 months), glomerular architecture
    Comparator
    Saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    improved cytoskeletal integrity (synaptopodin).
    1 context sentence
    Summary · context
    Baseline (24-month-old) mice were randomized to receive 8 weeks of SS-31, or saline, and killed at 26 months of age.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In aged mice, SS‑31 treatment was accompanied by higher glomerular endothelial cell density (CD31) versus saline.

    In plain wordsIn old mice, SS‑31 treatment went with more blood-vessel lining cells in the kidney filters compared with saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseGlomerular endothelial cell density (CD31)
    Study

    mousen: not reported in source

    aged mice (26 months), glomerular architecture
    Comparator
    Saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    This was accompanied by higher glomerular endothelial cell density (CD31).
    1 context sentence
    Summary · context
    Baseline (24-month-old) mice were randomized to receive 8 weeks of SS-31, or saline, and killed at 26 months of age.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.